Psoriasis Drugs Market 2027 By Therapeutic Class, Treatment and Geography | The Insight Partners

Psoriasis Drugs Market to 2027 - Global Analysis and Forecasts by Therapeutic Class (Vitamin-D Analogues, Interleukin Inhibitors, Tumor Necrosis Factor Inhibitors, and Other Therapeutic Class); Treatment (Topicals, Systemic and Biologics) and Geography

Report Code: TIPRE00004962 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Psoriasis is a medical condition in which red scales or patches are visible on the body especially near areas such as, elbow, knees and scalp. The condition occurs due to an overactive immune system. Some of the common symptoms include flaking, inflammation of the skin. Common treatments for psoriasis include, steroid creams, occlusion, light therapy and oral medications, such as biologics. It appears in most of the cases in the age 16-22 years.

MARKET DYNAMICS
The psoriasis drugs market is anticipated to grow in the forecast period owing to increasing healthcare expenditure and growing use of combination therapies. The market is likely to experience the growth due to opportunities in research and developments in the pipeline drugs for psoriasis.

MARKET SCOPE
The "Global Psoriasis Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of psoriasis drugs market with detailed market segmentation by therapeutic class, treatment and geography. The global psoriasis drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading psoriasis drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global psoriasis drugs market is segmented on the basis of therapeutic class and treatment. Based on therapeutic class, the market is classified as vitamin-D analogues, interleukin inhibitors, tumor necrosis factor inhibitors, and other therapeutic class. Based on treatment, the psoriasis drugs market is divided as topicals, systemic and biologics.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global psoriasis drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The psoriasis drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting psoriasis drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the psoriasis drugs market in these regions.

MARKET PLAYERS
The reports cover key developments in the psoriasis drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from psoriasis drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for psoriasis drugs market in the global market. Below mentioned is the list of few companies engaged in the psoriasis drugs market.

The report also includes the profiles of key psoriasis drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • CELGENE CORPORATION
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfzer Inc.
  • UCB S.A.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Psoriasis Drugs Market - By Therapeutic Class
1.3.2 Psoriasis Drugs Market - By Treatment
1.3.3 Psoriasis Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PSORIASIS DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PSORIASIS DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PSORIASIS DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. PSORIASIS DRUGS - GLOBAL MARKET OVERVIEW
6.2. PSORIASIS DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. PSORIASIS DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - THERAPEUTIC CLASS
7.1. OVERVIEW
7.2. THERAPEUTIC CLASS MARKET FORECASTS AND ANALYSIS
7.3. VITAMIN-D ANALOGUES
7.3.1. Overview
7.3.2. Vitamin-D Analogues Market Forecast and Analysis
7.4. INTERLEUKIN INHIBITORS
7.4.1. Overview
7.4.2. Interleukin Inhibitors Market Forecast and Analysis
7.5. TUMOR NECROSIS FACTOR INHIBITORS
7.5.1. Overview
7.5.2. Tumor Necrosis Factor Inhibitors Market Forecast and Analysis
7.6. OTHER THERAPEUTIC CLASS
7.6.1. Overview
7.6.2. Other Therapeutic Class Market Forecast and Analysis
8. PSORIASIS DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - TREATMENT
8.1. OVERVIEW
8.2. TREATMENT MARKET FORECASTS AND ANALYSIS
8.3. TOPICALS
8.3.1. Overview
8.3.2. Topicals Market Forecast and Analysis
8.4. SYSTEMIC
8.4.1. Overview
8.4.2. Systemic Market Forecast and Analysis
8.5. BIOLOGICS
8.5.1. Overview
8.5.2. Biologics Market Forecast and Analysis
9. PSORIASIS DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Psoriasis Drugs Market Overview
9.1.2 North America Psoriasis Drugs Market Forecasts and Analysis
9.1.3 North America Psoriasis Drugs Market Forecasts and Analysis - By Therapeutic Class
9.1.4 North America Psoriasis Drugs Market Forecasts and Analysis - By Treatment
9.1.5 North America Psoriasis Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Psoriasis Drugs Market
9.1.5.1.1 United States Psoriasis Drugs Market by Therapeutic Class
9.1.5.1.2 United States Psoriasis Drugs Market by Treatment
9.1.5.2 Canada Psoriasis Drugs Market
9.1.5.2.1 Canada Psoriasis Drugs Market by Therapeutic Class
9.1.5.2.2 Canada Psoriasis Drugs Market by Treatment
9.1.5.3 Mexico Psoriasis Drugs Market
9.1.5.3.1 Mexico Psoriasis Drugs Market by Therapeutic Class
9.1.5.3.2 Mexico Psoriasis Drugs Market by Treatment
9.2. EUROPE
9.2.1 Europe Psoriasis Drugs Market Overview
9.2.2 Europe Psoriasis Drugs Market Forecasts and Analysis
9.2.3 Europe Psoriasis Drugs Market Forecasts and Analysis - By Therapeutic Class
9.2.4 Europe Psoriasis Drugs Market Forecasts and Analysis - By Treatment
9.2.5 Europe Psoriasis Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Psoriasis Drugs Market
9.2.5.1.1 Germany Psoriasis Drugs Market by Therapeutic Class
9.2.5.1.2 Germany Psoriasis Drugs Market by Treatment
9.2.5.2 France Psoriasis Drugs Market
9.2.5.2.1 France Psoriasis Drugs Market by Therapeutic Class
9.2.5.2.2 France Psoriasis Drugs Market by Treatment
9.2.5.3 Italy Psoriasis Drugs Market
9.2.5.3.1 Italy Psoriasis Drugs Market by Therapeutic Class
9.2.5.3.2 Italy Psoriasis Drugs Market by Treatment
9.2.5.4 Spain Psoriasis Drugs Market
9.2.5.4.1 Spain Psoriasis Drugs Market by Therapeutic Class
9.2.5.4.2 Spain Psoriasis Drugs Market by Treatment
9.2.5.5 United Kingdom Psoriasis Drugs Market
9.2.5.5.1 United Kingdom Psoriasis Drugs Market by Therapeutic Class
9.2.5.5.2 United Kingdom Psoriasis Drugs Market by Treatment
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Psoriasis Drugs Market Overview
9.3.2 Asia-Pacific Psoriasis Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Psoriasis Drugs Market Forecasts and Analysis - By Therapeutic Class
9.3.4 Asia-Pacific Psoriasis Drugs Market Forecasts and Analysis - By Treatment
9.3.5 Asia-Pacific Psoriasis Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Psoriasis Drugs Market
9.3.5.1.1 Australia Psoriasis Drugs Market by Therapeutic Class
9.3.5.1.2 Australia Psoriasis Drugs Market by Treatment
9.3.5.2 China Psoriasis Drugs Market
9.3.5.2.1 China Psoriasis Drugs Market by Therapeutic Class
9.3.5.2.2 China Psoriasis Drugs Market by Treatment
9.3.5.3 India Psoriasis Drugs Market
9.3.5.3.1 India Psoriasis Drugs Market by Therapeutic Class
9.3.5.3.2 India Psoriasis Drugs Market by Treatment
9.3.5.4 Japan Psoriasis Drugs Market
9.3.5.4.1 Japan Psoriasis Drugs Market by Therapeutic Class
9.3.5.4.2 Japan Psoriasis Drugs Market by Treatment
9.3.5.5 South Korea Psoriasis Drugs Market
9.3.5.5.1 South Korea Psoriasis Drugs Market by Therapeutic Class
9.3.5.5.2 South Korea Psoriasis Drugs Market by Treatment
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Psoriasis Drugs Market Overview
9.4.2 Middle East and Africa Psoriasis Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Psoriasis Drugs Market Forecasts and Analysis - By Therapeutic Class
9.4.4 Middle East and Africa Psoriasis Drugs Market Forecasts and Analysis - By Treatment
9.4.5 Middle East and Africa Psoriasis Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Psoriasis Drugs Market
9.4.5.1.1 South Africa Psoriasis Drugs Market by Therapeutic Class
9.4.5.1.2 South Africa Psoriasis Drugs Market by Treatment
9.4.5.2 Saudi Arabia Psoriasis Drugs Market
9.4.5.2.1 Saudi Arabia Psoriasis Drugs Market by Therapeutic Class
9.4.5.2.2 Saudi Arabia Psoriasis Drugs Market by Treatment
9.4.5.3 U.A.E Psoriasis Drugs Market
9.4.5.3.1 U.A.E Psoriasis Drugs Market by Therapeutic Class
9.4.5.3.2 U.A.E Psoriasis Drugs Market by Treatment
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Psoriasis Drugs Market Overview
9.5.2 South and Central America Psoriasis Drugs Market Forecasts and Analysis
9.5.3 South and Central America Psoriasis Drugs Market Forecasts and Analysis - By Therapeutic Class
9.5.4 South and Central America Psoriasis Drugs Market Forecasts and Analysis - By Treatment
9.5.5 South and Central America Psoriasis Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Psoriasis Drugs Market
9.5.5.1.1 Brazil Psoriasis Drugs Market by Therapeutic Class
9.5.5.1.2 Brazil Psoriasis Drugs Market by Treatment
9.5.5.2 Argentina Psoriasis Drugs Market
9.5.5.2.1 Argentina Psoriasis Drugs Market by Therapeutic Class
9.5.5.2.2 Argentina Psoriasis Drugs Market by Treatment
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. PSORIASIS DRUGS MARKET, KEY COMPANY PROFILES
11.1. ABBVIE INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. AMGEN INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ASTRAZENECA
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. CELGENE CORPORATION
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. ELI LILLY AND COMPANY
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. JOHNSON & JOHNSON SERVICES, INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. MERCK AND CO., INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. NOVARTIS PHARMACEUTICALS CORPORATION
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. PFIZER INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. UCB S.A.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. AbbVie Inc.
2. Amgen Inc.
3. AstraZeneca
4. CELGENE CORPORATION
5. Eli Lilly and Company
6. Johnson & Johnson Services, Inc.
7. Merck & Co., Inc.
8. Novartis Pharmaceuticals Corporation
9. Pfizer Inc.
10. UCB S. A.